.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Predict branded drug patent expiration
  • Identify first generic entrants

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Baxter
Deloitte
Farmers Insurance
Harvard Business School
Fish and Richardson
Express Scripts
Cipla
US Army
Dow
QuintilesIMS

Generated: June 25, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,081,255

« Back to Dashboard

Which drugs does patent 7,081,255 protect, and when does it expire?


Patent 7,081,255 protects ONMEL and is included in one NDA.

This patent has forty-one patent family members in thirty-three countries.

Summary for Patent: 7,081,255

Title:Antifungal compositions with improved bioavailability
Abstract:The present invention is concerned with novel pharmaceutical compositions of itraconazole which can be administered to a mammal suffering from a fungal infection, whereby a single such dosage form can be administered once daily, and in addition at any time of the day independently of the food taken in by said mammal. These novel compositions comprise particles obtainable by melt-extruding a mixture comprising itraconazole and an appropriate water-soluble polymer and subsequently milling said melt-extruded mixture.
Inventor(s): Baert; Lieven Elvire Colette (Brugge, BE), Verreck; Geert (Malle, BE), Thone; Dany (Beerse, BE)
Assignee: Janssen Pharmaceutica, N.V. (Beerse, BE)
Application Number:10/218,851
Patent Claim Types:
see list of patent claims
Compound; Dosage form; Formulation; Composition; Device; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Sebela Ireland Ltd
ONMEL
itraconazole
TABLET;ORAL022484-001Apr 29, 2010RXYesYes7,081,255► SubscribeY ONYCHOMYCOSIS OF THE TOENAIL CAUSED BY TRICOPHYTON RUBRUM OR TRICHOPHYTON MENTAGROPHYTES, ONCE DAILY USE FOR 12 CONSECUTIVE WEEKS
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 7,081,255

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
96201430May 20, 1996
97200698Mar 07, 1997

Non-Orange Book Patents for Patent: 7,081,255

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,509,038 Antifungal compositions with improved bioavailability► Subscribe
8,591,948Antifungal compositions with improved bioavailability► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,081,255

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
CroatiaP970270► Subscribe
Hong Kong1018002► Subscribe
European Patent Office0904060► Subscribe
Israel124935► Subscribe
Hungary227745► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Mallinckrodt
Chubb
Chinese Patent Office
Fuji
Cerilliant
Federal Trade Commission
Moodys
Merck
Covington
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot